Analyzing Kura Oncology (KURA) & Its Peers

Kura Oncology (NASDAQ: KURA) is one of 287 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Kura Oncology to similar companies based on the strength of its valuation, profitability, institutional ownership, dividends, analyst recommendations, earnings and risk.

Profitability

This table compares Kura Oncology and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kura Oncology N/A -53.40% -44.08%
Kura Oncology Competitors -5,441.68% -162.70% -35.92%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Kura Oncology and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kura Oncology 0 0 6 0 3.00
Kura Oncology Competitors 925 3348 11856 237 2.70

Kura Oncology presently has a consensus target price of $18.30, suggesting a potential upside of 21.19%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.90%. Given Kura Oncology’s peers higher probable upside, analysts clearly believe Kura Oncology has less favorable growth aspects than its peers.

Earnings and Valuation

This table compares Kura Oncology and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Kura Oncology N/A -$27.56 million -9.74
Kura Oncology Competitors $290.27 million $35.99 million 57.95

Kura Oncology’s peers have higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

64.3% of Kura Oncology shares are owned by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 21.8% of Kura Oncology shares are owned by insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Kura Oncology Company Profile

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply